357 related articles for article (PubMed ID: 26492266)
1. Perspective of Use of Antiviral Peptides against Influenza Virus.
Skalickova S; Heger Z; Krejcova L; Pekarik V; Bastl K; Janda J; Kostolansky F; Vareckova E; Zitka O; Adam V; Kizek R
Viruses; 2015 Oct; 7(10):5428-42. PubMed ID: 26492266
[TBL] [Abstract][Full Text] [Related]
2. Antiviral Peptides as Anti-Influenza Agents.
Agamennone M; Fantacuzzi M; Vivenzio G; Scala MC; Campiglia P; Superti F; Sala M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232735
[TBL] [Abstract][Full Text] [Related]
3. Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.
Bai Y; Jones JC; Wong SS; Zanin M
Viruses; 2021 Apr; 13(4):. PubMed ID: 33917376
[TBL] [Abstract][Full Text] [Related]
4. Antiviral strategies against influenza virus: towards new therapeutic approaches.
Loregian A; Mercorelli B; Nannetti G; Compagnin C; Palù G
Cell Mol Life Sci; 2014 Oct; 71(19):3659-83. PubMed ID: 24699705
[TBL] [Abstract][Full Text] [Related]
5. A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment.
Hoffmann J; Schneider C; Heinbockel L; Brandenburg K; Reimer R; Gabriel G
Antiviral Res; 2014 Apr; 104():23-33. PubMed ID: 24486207
[TBL] [Abstract][Full Text] [Related]
6. Drugs in development for influenza.
Boltz DA; Aldridge JR; Webster RG; Govorkova EA
Drugs; 2010 Jul; 70(11):1349-62. PubMed ID: 20614944
[TBL] [Abstract][Full Text] [Related]
7. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy.
Pizzorno A; Padey B; Terrier O; Rosa-Calatrava M
Front Immunol; 2019; 10():531. PubMed ID: 30941148
[TBL] [Abstract][Full Text] [Related]
8. Influenza viruses: basic biology and potential drug targets.
Basler CF
Infect Disord Drug Targets; 2007 Dec; 7(4):282-93. PubMed ID: 18220960
[TBL] [Abstract][Full Text] [Related]
9. New influenza A Virus Entry Inhibitors Derived from the Viral Fusion Peptides.
Wu W; Lin D; Shen X; Li F; Fang Y; Li K; Xun T; Yang G; Yang J; Liu S; He J
PLoS One; 2015; 10(9):e0138426. PubMed ID: 26382764
[TBL] [Abstract][Full Text] [Related]
10. Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections.
Ludwig S
Biol Chem; 2011 Oct; 392(10):837-47. PubMed ID: 21823902
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle.
Yang F; Pang B; Lai KK; Cheung NN; Dai J; Zhang W; Zhang J; Chan KH; Chen H; Sze KH; Zhang H; Hao Q; Yang D; Yuen KY; Kao RY
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627391
[TBL] [Abstract][Full Text] [Related]
12. Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection.
Hu CJ; Chen YT; Fang ZS; Chang WS; Chen HW
Int J Nanomedicine; 2018; 13():8579-8593. PubMed ID: 30587980
[TBL] [Abstract][Full Text] [Related]
13. Emerging antiviral strategies to interfere with influenza virus entry.
Vanderlinden E; Naesens L
Med Res Rev; 2014 Mar; 34(2):301-39. PubMed ID: 23801557
[TBL] [Abstract][Full Text] [Related]
14. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M
Front Immunol; 2019; 10():60. PubMed ID: 30761132
[TBL] [Abstract][Full Text] [Related]
15. Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means.
Terrier O; Slama-Schwok A
Adv Exp Med Biol; 2021; 1322():195-218. PubMed ID: 34258742
[TBL] [Abstract][Full Text] [Related]
16. Influenza chemotherapy: a review of the present state of art and of new drugs in development.
Lüscher-Mattli M
Arch Virol; 2000; 145(11):2233-48. PubMed ID: 11205114
[TBL] [Abstract][Full Text] [Related]
17. Influenza virus cell entry and targeted antiviral development.
Zhu M; Anirudhan V; Du R; Rong L; Cui Q
J Med Virol; 2023 Nov; 95(11):e29181. PubMed ID: 37930075
[TBL] [Abstract][Full Text] [Related]
18. Influenza Virus Entry inhibitors.
Yang J; Liu S
Adv Exp Med Biol; 2022; 1366():123-135. PubMed ID: 35412138
[TBL] [Abstract][Full Text] [Related]
19. Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models.
Saito M; Itoh Y; Yasui F; Munakata T; Yamane D; Ozawa M; Ito R; Katoh T; Ishigaki H; Nakayama M; Shichinohe S; Yamaji K; Yamamoto N; Ikejiri A; Honda T; Sanada T; Sakoda Y; Kida H; Le TQM; Kawaoka Y; Ogasawara K; Tsukiyama-Kohara K; Suga H; Kohara M
Nat Commun; 2021 May; 12(1):2654. PubMed ID: 33976181
[TBL] [Abstract][Full Text] [Related]
20. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Davis CT; Villanueva JM; Fry AM; Gubareva LV
J Virol; 2015 May; 89(10):5419-26. PubMed ID: 25740997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
